Search clinical trials for: Lurasidone Hydrochloride

Total 7352 results

Sumitomo Pharma (Suzhou) Co., Ltd.
Xuhui Central Hospital, Shanghai

Completed

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

Schizophrenia

China
University of California, Irvine
Dainippon Sumitomo Pharma America

Completed

A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone

Schizophrenia

United States
Sunovion

Completed

Safety and Tolerability Study of Drug to Treat Schizophrenia

Schizophrenia

United States
Sunovion

Completed

A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

Schizophrenia

United States
Sunovion

Withdrawn

Major Depressive Disorder With Mixed Features (RESOLVE2)

Major Depressive Disorder

United States
Sunovion

Completed

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

Schizophrenia

United States
Massachusetts General Hospital

Withdrawn

Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old

Bipolar Disorder | Mania | Bipolar I | Bipolar II | Bipolar Spectrum Disorder

United States
Sunovion

Completed

Lurasidone Pediatric Autism Study

Autism

United States
Sunovion

Completed

Pediatric Schizophrenia Efficacy and Safety Study

Schizophrenia

France, United States, Korea, Republic of, Poland, Spain, Puerto Rico, Colombia, Hungary, Bulgaria, Mexico, Malaysia, Philippines, Romania, Russian Federation, Ukraine, Belgium, United Kingdom
University of North Carolina, Chapel Hill
Foundation of Hope, North Carolina

Completed

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Autistic Disorder | Child Development Disorders, Pervasive | Psychosis NOS | Bipolar I Disorder | Asperger Syndrome | Bipolar II Disorder | Severe Major Depression With Psychotic Features | Mood Disorder NOS | Single Episode Major Depression... and other conditions

United States
Sunovion

Completed

Lurasidone Low-Dose - High-Dose Study Study

Schizophrenia

United States, Ukraine, Romania, Slovakia, Colombia, Russian Federation
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Recruiting

Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU) (MARYLU)

Schizophrenia

Italy
Nazlin Walji

Recruiting

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients (ELICE_BD)

Bipolar Disorder

United States, Canada, Japan, United Kingdom
New York State Psychiatric Institute
Columbia University

Completed

18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder

Bipolar Depression

United States
Standard Chem. & Pharm. Co., Ltd.

Completed

A Study of Lurasidone HCl in Subjects With Schizophrenia

Schizophrenia

Taiwan
Sunovion

Completed

Lurasidone Extended Use Study

Schizophrenia | Bipolar Disorder

Canada, Serbia, Colombia, Czech Republic, India, Lithuania, Slovakia, Ukraine, France, Romania, South Africa, Russian Federation
Sunovion

Completed

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296 (PERSISTExt)

Bipolar I Disorder

United States, Poland, Bulgaria, Japan, Slovakia, Hungary, Russian Federation, Czech Republic, Argentina, Chile, France, Serbia
Sunovion

Completed

A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

Schizophrenia

United States
Sunovion

Completed

Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)

Bipolar Depression

United States, Czech Republic, India, France, Romania, Russian Federation, South Africa, Ukraine
Sunovion

Completed

Lithium Drug-Drug Interaction Study With Lurasidone HCl

Schizophrenia

United States
Sunovion

Completed

Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl

Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder

United States
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.
Sunovion

Terminated

A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression

Bipolar I Depression

China
Sumitomo Pharma Co., Ltd.

Completed

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Bipolar I Disorder

Japan, Lithuania, Malaysia, Philippines, Russian Federation, Slovakia, Taiwan, Ukraine
Sunovion

Completed

A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia

Schizophrenia

United States
Sumitomo Pharma (Suzhou) Co., Ltd.
Xuhui Central Hospital, Shanghai

Completed

Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects

Schizophrenia

China
Sunovion

Completed

Lurasidone Pediatric Bipolar Study (Illuminate)

Bipolar I Depression

United States, Korea, Republic of, Bulgaria, Poland, Mexico, Puerto Rico, Colombia, Hungary, France, Philippines, Ukraine
Sunovion

Completed

Lurasidone Pediatric Pharmacokinetics Study

Schizophrenia | Autism

United States
Northwestern University
Sunovion

Completed

High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia (HDL)

Schizophrenia

United States
Sunovion

Completed

A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder (Switch Ext)

Schizophrenia | Schizoaffective Disorder

United States
Sunovion

Completed

Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia

Schizophrenia

United States, Malaysia, Ukraine, India, Romania, Russian Federation, France
Sunovion

Completed

RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE

Pharmacokinetics | Metabolism

United States
Sunovion

Completed

Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression (PREVAIL3)

Bipolar Depression

United States, Canada, Colombia, Czech Republic, India, Japan, Lithuania, Peru, Slovakia, Ukraine
Sumitomo Pharma (Suzhou) Co., Ltd.

Terminated

The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine

Schizophrenia

China
Sumitomo Pharma (Suzhou) Co., Ltd.

Completed

The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients

Schizophrenia

China
Sunovion

Completed

A Twelve Week, Open Label Extension Study in Patients With Schizophrenia

Schizophrenia

United States, Slovakia, France, Italy, Serbia, South Africa, Russian Federation
New York State Psychiatric Institute
Sunovion

Completed

Biosignatures of Latuda for Bipolar Depression

Bipolar Depression

United States
University of British Columbia

Completed

Lurasidone and Cognition in Bipolar I Disorder

Bipolar I Disorder

Canada
Sunovion

Completed

Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex (PERSIST)

Bipolar I Disorder

United States, Croatia, Hungary, Poland, Serbia, Argentina, Japan, France, Slovakia, Australia, Russian Federation, Bulgaria, Chile, Czech Republic
Sunovion

Completed

Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose (RESOLVE 1)

Major Depressive Disorder With Mixed Features

United States, Serbia, Ukraine, Russian Federation, United Kingdom
Sunovion

Completed

Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression

Bipolar Depression

United States, Canada, Czech Republic, India, Lithuania, Peru, South Africa, France, Poland, Romania, Russian Federation, Ukraine, Colombia, Slovakia, Japan
Sunovion

Completed

Major Depressive Disorder With Mixed Features - Extension (RESOLVE3)

Major Depressive Disorder

United States
Sunovion

Completed

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

Schizophrenia | Schizoaffective Disorder

United States, Israel, Chile, South Africa, Argentina, Brazil, Croatia, Thailand
Sunovion

Completed

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

Schizophrenia

United States
Sunovion

Completed

Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia

Schizophrenia

United States, Lithuania, India, Philippines, Colombia
Sunovion

Completed

PEARL Schizophrenia Maintenance

Schizophrenia

United States, Serbia, South Africa, France, Italy, Russian Federation, Slovakia
Sunovion

Completed

Midazolam Drug-Drug Interaction Study With Lurasidone HCl

Schizophrenia Patients

United States
NeuroRx, Inc.
Target Health Inc.

Active, not recruiting

NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation (SBD-ASIB)

Suicidal Ideation | Bipolar Depression

United States
Sumitomo Pharma Co., Ltd.

Completed

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Bipolar Depression

Lithuania, Malaysia, Russian Federation, Slovakia, Ukraine, Japan, Philippines, Taiwan
Sunovion

Completed

A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents (SWITCHCore)

Schizophrenia | Schizoaffective Disorder

United States

Search clinical trials for: Lurasidone Hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations